PureTech Health

PRTC · LONDON

Price unavailable right now.

No price history for this range.

Latest news

Press releaseMay 13, 7:00 AM ETBusiness Wire
PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference
NewsApr 29, 7:11 AM ET
Earnings Scheduled For April 29, 2026
Press releaseApr 29, 2:01 AM ETBusiness Wire
PureTech Announces Annual Results for Year Ended December 31, 2025
Press releaseApr 29, 2:00 AM ETBusiness Wire
PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange
Press releaseApr 27, 7:05 AM ETBusiness Wire
PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors
Press releaseApr 22, 7:00 AM ETBusiness Wire
PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML)
Press releaseApr 13, 2:05 AM ETBusiness Wire
PureTech Health: Notice of Results
Press releaseApr 2, 8:19 AM ETBusiness Wire
PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine
Press releaseApr 2, 7:08 AM ETBusiness Wire
PureTech Founded Entity Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo™ in Healthy Volunteers
Press releaseMar 25, 2:04 PM ETBusiness Wire
PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans
Press releaseFeb 25, 2:00 AM ETBusiness Wire
PureTech to Present at the Leerink Partners Global Healthcare Conference
Press releaseFeb 19, 12:36 PM ETBusiness Wire
PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
Press releaseJan 6, 7:00 AM ETBusiness Wire
PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference
Press releaseDec 18, 2:00 AM ETBusiness Wire
PureTech Appoints Robert Lyne as Chief Executive Officer
Press releaseDec 8, 2:00 AM ETBusiness Wire
PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
Press releaseDec 5, 1:00 PM ETBusiness Wire
PureTech's Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
Press releaseNov 3, 9:00 AM ETBusiness Wire
PureTech's Founded Entity Gallop Oncology to Present New Data from Ongoing Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia (AML) at the American Society of Hematology (ASH) Annual Meeting
Press releaseOct 22, 2:00 AM ETBusiness Wire
PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group
Press releaseSep 29, 2:00 AM ETBusiness Wire
PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF
NewsSep 19, 10:31 AM ETAvi Kapoor
CoreWeave, Barrick Mining, FedEx And Other Big Stocks Moving Higher On Friday
Press releaseSep 11, 7:05 AM ETBusiness Wire
PureTech Founded Entity Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgo™ (SPT-320) in Healthy Volunteers
NewsAug 28, 4:32 AM ET
Earnings Scheduled For August 28, 2025
Press releaseAug 28, 2:00 AM ETBusiness Wire
PureTech Health plc – Half-Year Report
Press releaseAug 21, 7:00 AM ETBusiness Wire
PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF
Press releaseAug 18, 2:00 AM ETBusiness Wire
PureTech Health: Notice of Half-Yearly Results
Press releaseAug 13, 12:16 PM ETBusiness Wire
PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint
Press releaseAug 12, 7:00 AM ETBusiness Wire
PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases
Press releaseJul 17, 7:05 AM ETBusiness Wire
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo™ (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress
NewsJun 26, 12:12 PM ETNabaparna Bhattacharya
Why This Biotech Stock Just Doubled In A Single Day
NewsApr 30, 4:32 AM ET
Earnings Scheduled For April 30, 2025
NewsApr 30, 2:50 AM ET
PureTech Health FY EPS $0.21 Up From $(0.24) YoY, Sales $4.83M Up From $3.33M YoY
Press releaseApr 30, 2:00 AM ETBusiness Wire
PureTech Announces Annual Results for Year Ended December 31, 2024
NewsApr 8, 8:35 AM ETAvi Kapoor
Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
NewsDec 16, 6:37 AM ETAvi Kapoor
Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket
NewsSep 27, 7:56 AM ETVandana Singh
Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb's Cobenfy As First New Class Of Treatment In More Than 3 Decades
NewsSep 10, 8:32 AM ETAvi Kapoor
Rubrik Reports Q2 Results, Joins Ionis Pharmaceuticals, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Press releaseAug 28, 2:01 AM ETBusiness Wire
PureTech Health plc – Half-Year Report

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference

Earnings Scheduled For April 29, 2026

PureTech Announces Annual Results for Year Ended December 31, 2025

PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange

PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors

PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML)

PureTech Health: Notice of Results

PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine

PureTech Founded Entity Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo™ in Healthy Volunteers

PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans

PureTech to Present at the Leerink Partners Global Healthcare Conference

PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis

PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference

PureTech Appoints Robert Lyne as Chief Executive Officer

PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis

PureTech's Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

PureTech's Founded Entity Gallop Oncology to Present New Data from Ongoing Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia (AML) at the American Society of Hematology (ASH) Annual Meeting

PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group

PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF

CoreWeave, Barrick Mining, FedEx And Other Big Stocks Moving Higher On Friday

PureTech Founded Entity Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgo™ (SPT-320) in Healthy Volunteers

Earnings Scheduled For August 28, 2025

PureTech Health plc – Half-Year Report

PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF

PureTech Health: Notice of Half-Yearly Results

PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint

PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases

PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo™ (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress

Why This Biotech Stock Just Doubled In A Single Day

Earnings Scheduled For April 30, 2025

PureTech Health FY EPS $0.21 Up From $(0.24) YoY, Sales $4.83M Up From $3.33M YoY

PureTech Announces Annual Results for Year Ended December 31, 2024

Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket

Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb's Cobenfy As First New Class Of Treatment In More Than 3 Decades

Rubrik Reports Q2 Results, Joins Ionis Pharmaceuticals, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

PureTech Health plc – Half-Year Report